Literature DB >> 18996507

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Laura E Phelps1, Nancy Brutsche, Jazmin R Moral, David A Luckenbaugh, Husseini K Manji, Carlos A Zarate.   

Abstract

BACKGROUND: A high rate of comorbidity exists between mood disorders and alcohol dependence. Furthermore, both ketamine, a dissociative anesthetic with a recently described rapid-onset antidepressant effect, and ethanol are N-methyl-D-aspartate (NMDA) receptor antagonists. Previous investigations of healthy individuals with a family history of alcohol dependence have found that these individuals have an attenuated response to ketamine's perceptual disturbance and dysphoric effects similar to that found in individuals with a self-reported history of alcohol dependence. This study investigated whether a family history of alcohol dependence influences ketamine's initial antidepressant effect.
METHODS: Twenty-six subjects with DSM-IV treatment-resistant major depression were given an open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg) and rated using various depression scales at baseline, 40, 80, 120, and 230 min postinfusion. The primary outcome measure was Montgomery-Asberg Depression Rating Scale (MADRS) scores.
RESULTS: Subjects with a family history of alcohol dependence showed significantly greater improvement in MADRS scores compared with subjects who had no family history of alcohol dependence.
CONCLUSIONS: A family history of alcohol dependence appears to predict a rapid initial antidepressant response to an NMDA receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18996507      PMCID: PMC2727595          DOI: 10.1016/j.biopsych.2008.09.029

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  19 in total

1.  Rare outcomes, common treatments: analytic strategies using propensity scores.

Authors:  Leonard E Braitman; Paul R Rosenbaum
Journal:  Ann Intern Med       Date:  2002-10-15       Impact factor: 25.391

Review 2.  Clinical studies implementing glutamate neurotransmission in mood disorders.

Authors:  Gerard Sanacora; Douglas L Rothman; Graeme Mason; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

3.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

4.  Assessment of depression: the depression inventory.

Authors:  A T Beck; A Beamesderfer
Journal:  Mod Probl Pharmacopsychiatry       Date:  1974

Review 5.  NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.

Authors:  John H Krystal; Ismene L Petrakis; Evgeny Krupitsky; Christian Schutz; Louis Trevisan; D Cyril D'Souza
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

6.  Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit.

Authors:  Andrey B Petrenko; Tomohiro Yamakura; Naoshi Fujiwara; Ahmed R Askalany; Hiroshi Baba; Kenji Sakimura
Journal:  Anesth Analg       Date:  2004-10       Impact factor: 5.108

7.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

8.  Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism.

Authors:  Ismene L Petrakis; Diana Limoncelli; Ralitza Gueorguieva; Peter Jatlow; Nashaat N Boutros; Louis Trevisan; Joel Gelernter; John H Krystal
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

9.  Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior.

Authors:  Gunter Schumann; Monika Johann; Josef Frank; Ulrich Preuss; Norbert Dahmen; Manfred Laucht; Marcella Rietschel; Dan Rujescu; Anbarasu Lourdusamy; Toni-Kim Clarke; Kristina Krause; Anne Dyer; Martin Depner; Stefan Wellek; Jens Treutlein; Armin Szegedi; Ina Giegling; Sven Cichon; Dorothea Blomeyer; Andreas Heinz; Simon Heath; Mark Lathrop; Norbert Wodarz; Michael Soyka; Rainer Spanagel; Karl Mann
Journal:  Arch Gen Psychiatry       Date:  2008-07

Review 10.  The glutamatergic basis of human alcoholism.

Authors:  G Tsai; D R Gastfriend; J T Coyle
Journal:  Am J Psychiatry       Date:  1995-03       Impact factor: 18.112

View more
  82 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 3.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

4.  Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Gislaine T Rezin; Daiane B Fraga; Juliana F Daufenbach; Giselli Scaini; Joana Benedet; Natália Rochi; Emílio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-09-28       Impact factor: 3.575

Review 5.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 6.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

7.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

Review 8.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

9.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

10.  Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism.

Authors:  S Jamadar; E E DeVito; R E Jiantonio; S A Meda; M C Stevens; M N Potenza; J H Krystal; G D Pearlson
Journal:  Psychopharmacology (Berl)       Date:  2012-02-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.